09:56Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
06:49Orthotopic Implantation of Patient-Derived Cancer Cells in Mice Recapitulates Advanced Colorectal Cancer
06:59Establishment of Zebrafish Patient-Derived Xenografts from Pancreatic Cancer for Chemosensitivity Testing
06:46Competing-Risk Nomogram for Predicting Cancer-Specific Survival in Multiple Primary Colorectal Cancer Patients after Surgery
07:17An Orthotopic Resectional Mouse Model of Pancreatic Cancer
07:29Studying Pancreatic Cancer Stem Cell Characteristics for Developing New Treatment Strategies
You might also read
Articles linked to this work by shared authors, journal, and citation graph.
Updated: Jan 20, 2026

Patient-derived Heterogeneous Xenograft Model of Pancreatic Cancer Using Zebrafish Larvae as Hosts for Comparative Drug Assessment
Published on: April 30, 2019
Y Chen1,2, Y R Wang1, G C Deng1
1Department of Medical Oncology, Chinese People's Liberation Army (PLA) General Hospital and Chinese PLA Medical School, Beijing, 100853, China.
A decrease in cancer antigen 19-9 (CA19-9) levels during treatment is linked to better survival in pancreatic cancer patients, especially those with low platelet counts. This suggests a potential interaction between platelets and tumor cells.
Area of Science:
Background:
Purpose of the Study:
Main Methods:
Main Results:
Conclusions: